Page 15 - Haematologica May 2022

Editorials
ing role of a geriatric assessment in informing therapy selection and management.8
Disclosures
No conflicts of interest to disclose. With regard to work outside this publication, I provide consultancy services for AbbVie, Janssen, AstraZeneca, Beigene, Roche, Kite/Gilead, Celgene/BMS, Takeda, Kyowa-Kirin and ADCTherapeutics. My group has received a research grant from Pfizer.
References
1. DuMontier C, Uno H, Hshieh T, et al. Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica. 2022;107(5):1172-1180.
2. White MC, Holman DM, Boehm JE, et al. Age and cancer risk: a poten-
tially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7-S15. 3. Krok-Schoen JL, Fisher JL, Stephens JA, et al. Incidence and survival of hematological cancers among adults ages ≥75 years. Cancer Med.
2018;7(7):3425-3433.
4. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and
management of vulnerabilities in older patients receiving chemother- apy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326-2347.
5. Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018;131(5):515-524.
6.Scheepers ERM, Vondeling AM, Thielen N, van der Griend R, Stauder R, Hamaker ME. Geriatric assessment in older patients with a hematologic malignancy: a systematic review. Haematologica. 2020;105(6):1484-1493.
7. Cannella L, Efficace F, Giesinger J. How should we assess patient- reported outcomes in the onco-hematology clinic? Curr Opin Support Palliat Care. 2018;12(4):522-529.
8. Rosko AE, Cordoba R, Abel G, et al. Advances in management for older adults with hematologic malignancies. J Clin Oncol. 2021;39 (19):2102-2114.
haematologica | 2022; 107(5)
1023